Apellis (NASDAQ: APLS) CFO reports bona fide stock gifts

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported two bona fide gift transfers of common stock. On April 17, 2026, he gifted a total of 22,192 shares, including 11,096 shares transferred to The Timothy E Sullivan Irrevocable Trust of 2023.

After these gifts, the filing shows 71,492 shares held indirectly through the irrevocable trust and 140,945 shares held directly. The footnote states he disclaims beneficial ownership of shares held by the trust except to the extent of his pecuniary interest.

Insider Trade Summary

22,192 shares gifted

Mixed 2 txns

Insider Sullivan Timothy Eugene

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Gift	Common Stock	11,096	$0.00	--
Gift	Common Stock	11,096	$0.00	--

Holdings After Transaction: Common Stock — 140,945 shares (Direct, null); Common Stock — 71,492 shares (Indirect, Indirect Owner (The Timothy E Sullivan Irrevocable Trust of 2023))

Footnotes (1)

[object Object]

Key Figures

Gifted shares (total): 22,192 shares Gifted shares per transaction: 11,096 shares Direct holdings after transactions: 140,945 shares +2 more

5 metrics

Gifted shares (total) 22,192 shares Bona fide gifts of common stock on April 17, 2026

Gifted shares per transaction 11,096 shares Each of two bona fide gift transfers

Direct holdings after transactions 140,945 shares Common stock held directly by CFO after gifts

Indirect holdings after transactions 71,492 shares Common stock held through The Timothy E Sullivan Irrevocable Trust of 2023

Gift transaction count 2 transactions Both coded as bona fide gifts (Code G)

Key Terms

bona fide gift, irrevocable trust, beneficial ownership, indirect ownership, +1 more

5 terms

bona fide gift financial

"Both transactions are described with the code G and the label "Bona fide gift"."

irrevocable trust financial

"Shares were transferred to The Timothy E Sullivan Irrevocable Trust of 2023."

beneficial ownership financial

"The reporting person disclaims beneficial ownership over the shares held by the trust."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

indirect ownership financial

"Nature of ownership is listed as Indirect Owner for the trust-held shares."

pecuniary interest financial

"He disclaims beneficial ownership except to the extent of his pecuniary interest therein."

Form 4 Insider Transactions: What Each Field Means →

04/20/2026 - 04:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sullivan Timothy Eugene

(Last)

(First)

(Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM

MASSACHUSETTS

02451

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/17/2026		G		11,096	D	$0	140,945	D
Common Stock	04/17/2026		G		11,096	A	$0	71,492	I⁽¹⁾	Indirect Owner (The Timothy E Sullivan Irrevocable Trust of 2023)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On April 17, 2026, the reporting person transferred 11,096 shares to The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.

	/s/ David Watson, attorney-in-fact for Timothy Sullivan	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Apellis (APLS) report for its CFO?

Apellis reported that CFO Timothy Eugene Sullivan made two bona fide gift transfers of common stock totaling 22,192 shares. These are non-market gifts, not open-market purchases or sales, and therefore do not directly reflect trading activity in Apellis shares.

How many Apellis (APLS) shares did the CFO gift in this Form 4?

The filing shows gifts totaling 22,192 common shares: 11,096 shares in each of two separate bona fide gift transactions on April 17, 2026. One gift went to an irrevocable trust associated with the CFO, while the other is reported as a direct ownership disposition.

How many Apellis (APLS) shares does the CFO hold after the reported gifts?

After the gifts, the Form 4 reports that Timothy Eugene Sullivan holds 140,945 Apellis common shares directly and 71,492 shares indirectly through The Timothy E Sullivan Irrevocable Trust of 2023. These post-transaction balances show he retains a substantial equity stake in the company.

Was the Apellis (APLS) CFO’s Form 4 transaction a stock sale?

No. Both reported transactions are coded as bona fide gifts, meaning shares were transferred without sale proceeds. This distinguishes the moves from open-market sales and suggests estate, family, or other non-market transfers rather than a decision to sell shares for cash.

What is The Timothy E Sullivan Irrevocable Trust of 2023 in relation to Apellis (APLS)?

The trust is an entity that now holds 71,492 Apellis shares after receiving 11,096 gifted shares from the CFO. A trustee, Patrick O. Collins, oversees it, and Sullivan disclaims beneficial ownership of those shares except for any pecuniary interest he may have.

Does the Apellis (APLS) CFO’s Form 4 mention beneficial ownership disclaimers?

Yes. The footnote explains that Timothy Eugene Sullivan disclaims beneficial ownership of shares held by The Timothy E Sullivan Irrevocable Trust of 2023, except to the extent of his pecuniary interest. This clarifies how those indirectly held shares are treated for reporting purposes.